表紙
市場調查報告書

照護現場 (POC) 診斷的全球市場 - 至2024年的預測:葡萄糖,感染疾病 (C型肝炎,流感,呼吸系統) 、血液凝固

Point of Care Diagnostics Market by Product (Glucose, Infectious Disease (Hepatitis C, Influenza, Respiratory), Coagulation), Platform (Microfluidics, Immunoassays), Mode (Prescription & OTC), End-User (Hospitals, Home Care) - Global Forecast to 2024

出版商 MarketsandMarkets 商品編碼 298728
出版日期 內容資訊 英文 219 Pages
訂單完成後即時交付
價格
Back to Top
照護現場 (POC) 診斷的全球市場 - 至2024年的預測:葡萄糖,感染疾病 (C型肝炎,流感,呼吸系統) 、血液凝固 Point of Care Diagnostics Market by Product (Glucose, Infectious Disease (Hepatitis C, Influenza, Respiratory), Coagulation), Platform (Microfluidics, Immunoassays), Mode (Prescription & OTC), End-User (Hospitals, Home Care) - Global Forecast to 2024
出版日期: 2019年11月21日內容資訊: 英文 219 Pages
簡介

全球照護現場 (POC) 診斷市場預計將從2019年的285億美元,擴大到2024年467億美元。市場在2019年∼2024年間,預測將以年複合成長率 (CAGR) 10.4%的速度成長。

本報告提供全球照護現場 (POC) 診斷市場相關調查分析,市場概要,產業趨勢,各市場區隔的市場分析,競爭情形,主要企業等相關的系統性資訊。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 重要考察

  • 照護現場 (POC) 診斷市場概要
  • 照護現場 (POC) 診斷市場佔有率:各產品
  • 照護現場 (POC) 診斷各市場地區概述

第5章 市場概要

  • 簡介
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 機會
    • 課題
    • 新興用途

第6章 照護現場 (POC) 診斷的全球市場:各產品

  • 簡介
  • 葡萄糖監測產品
  • 心血管代謝監測產品
  • 傳染病檢查產品
  • 血液凝固監測產品
  • 妊娠、妊娠檢驗產品
  • 腫瘤/癌症標記檢驗產品
  • 尿液檢查產品
  • 膽固醇檢驗產品
  • 血液學的檢驗產品
  • 藥物濫用檢測產品
  • 糞便潛血反應檢驗產品
  • 其他

第7章 照護現場 (POC) 診斷的全球市場:各平台

  • 簡介
  • 側流化驗
  • 沾醬棒
  • 微射流
  • 分子診斷
  • 免疫測量

第8章 照護現場 (POC) 診斷的全球市場:各購買方法

  • 簡介
  • 處方式
  • OTC

第9章 照護現場 (POC) 診斷的全球市場:各終端用戶

  • 簡介
  • 門診病人醫療
  • 醫院/重症加護中心
  • 居家醫療
  • 其他

第10章 照護現場 (POC) 診斷的全球市場:各地區

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 南美

第11章 競爭情形

  • 簡介
  • 市場佔有率分析
  • 競爭模式
  • 供應商概要
  • 選擇供應商標準
  • 供應商分析

第12章 企業簡介

  • ABBOTT LABORATORIES
  • BECTON, DICKINSON AND COMPANY
  • CHEMBIO DIAGNOSTICS
  • DANAHER CORPORATION
  • JOHNSON & JOHNSON
  • ROCHE DIAGNOSTICS (F. HOFFMANN-LA ROCHE LTD.的子公司)
  • SIEMENS HEALTHINEERS GROUP
  • EKF DIAGNOSTICS
  • QUIDEL
  • TRINITY BIOTECH
  • ACCUBIOTECH
  • INSTRUMENTATION LABORATORY
  • NOVA BIOMEDICAL 205
  • PTS DIAGNOSTICS (SINOCARE, INC.的一部分)
  • SEKISUI DIAGNOSTICS (Japan)

第13章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MD 2702

"The point-of-care diagnostics market is projected to grow at a CAGR of 10.4% from 2019 to 2024."

The global point-of-care diagnostics market is projected to reach USD 46.7 billion by 2024 from USD 28.5 billion in 2019, at a CAGR of 10.4%. Factors such as the high prevalence of infectious diseases in developing countries, increasing incidence of target conditions, and increasing inclination toward home healthcare across the globe are driving the market for point-of-care diagnostics. However, product recalls, a lack of alignment with test results obtained from laboratories, stringent & time-consuming approval policies, and a reluctance to change existing diagnostic practices are expected to restrain market growth.

"The glucose monitoring products segment is expected to command the largest share of the POC diagnostics market in 2019."

Based on product, the point-of-care diagnostics market is segmented into glucose monitoring, infectious disease testing, cardiometabolic monitoring, coagulation monitoring, hematology testing, urinalysis testing, cholesterol testing, drugs-of-abuse testing, tumor/cancer markers, pregnancy & fertility testing, fecal occult testing, and other POC products. The glucose monitoring products segment is expected to command the largest share of the market in 2019. The increasing number of POC glucose monitoring devices, coupled with the growing prevalence of diabetes, is expected to drive the growth of the POC diagnostics market for glucose monitoring products in the coming years.

"The microfluidics segment is expected to register the highest growth rate in the POC diagnostics market, by platform, during the forecast period."

On the basis of platform, the point-of-care diagnostics market is segmented into lateral flow assays, dipsticks, microfluidics, molecular diagnostics, and immunoassays. The microfluidics segment is expected to register the highest growth rate during the forecast period. Technological advancements and increasing initiatives by market players for developing novel microfluidics-based POC products are propelling the growth of the microfluidics market.

"The Asia Pacific market is expected to register the highest CAGR during the forecast period."

The point-of-care diagnostics market, by region, is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific market is expected to register the highest growth rate during the forecast period, due to the growing initiatives by market players, increasing patient population base, and rising number of partnerships and joint ventures in this region.

Breakdown of supply-side primary interviews:

  • By Company Type: Tier 1: 25%, Tier 2: 30%, and Tier 3: 45%
  • By Designation: C-level: 26%, Director-level: 30%, and Others: 44%
  • By Region: North America: 34%, Europe: 26%, APAC: 23%, and the RoW: 17%

Prominent players of the point-of-care diagnostics market are: Abbott (US), Roche (Switzerland), Siemens (Germany), Danaher (US), Becton, Dickinson, and Company (US), Johnson & Johnson (US), Instrumentation Laboratory (US), PTS Diagnostics (US), Quidel (US), Chembio Diagnostic Systems (US), Sekisui Diagnostics (US), Nova Biomedical (US), EKF Diagnostics (UK), AccuBioTech (China), and Trinity Biotech (Ireland).

Research Coverage:

This report studies the point-of-care diagnostics market based on product, platform, mode of purchase, end user, and region. The report also studies factors affecting market growth, analyzes opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends. The report forecasts the revenue of the market segments with respect to the five key regions and their respective countries.

Key Benefits of Buying the Report:

From an insights perspective, this research report has focused on various levels of analysis, such as market share analysis of top players and company profiles, which together comprise and discuss basic views on the competitive landscape, emerging segments of the point-of-care diagnostics market, and high-growth regions and their drivers, restraints, challenges, and opportunities. The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, will help firms garner greater market shares.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
    • 1.2.1 MARKETS COVERED
    • 1.2.2 YEARS CONSIDERED FOR THE STUDY
  • 1.3 CURRENCY
  • 1.4 LIMITATIONS
  • 1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Key data from primary sources
  • 2.2 MARKET SIZE ESTIMATION
    • 2.2.1 PRODUCT-BASED MARKET ESTIMATION
    • 2.2.2 MARKET SIZE ESTIMATION: OVERALL POINT-OF-CARE DIAGNOSTICS MARKET
    • 2.2.3 PRIMARY RESEARCH VALIDATION
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.4 RESEARCH LIMITATIONS & ASSUMPTIONS
    • 2.4.1 LIMITATIONS
    • 2.4.2 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 POC DIAGNOSTICS MARKET OVERVIEW
  • 4.2 POC DIAGNOSTICS MARKET SHARE, BY PRODUCT
  • 4.3 GEOGRAPHIC SNAPSHOT OF THE POC DIAGNOSTICS MARKET

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 High prevalence of infectious diseases in developing countries
      • 5.2.1.2 Increasing incidence of target conditions
      • 5.2.1.3 Growing government support
      • 5.2.1.4 Shortage of skilled laboratory technicians
      • 5.2.1.5 Rising number of CLIA-waived POC tests
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Pricing pressure owing to reimbursement cuts and budget constraints
      • 5.2.2.2 Stringent and time-consuming regulatory policies
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Emerging markets
      • 5.2.3.2 Healthcare decentralization-converting lab tests to POC tests
      • 5.2.3.3 Increasing awareness through conferences and events
      • 5.2.3.4 POC tests with multiplexing capabilities
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Lack of alignment with definitive central lab methods
      • 5.2.4.2 Inadequate knowledge about the use of POC devices in professional settings
      • 5.2.4.3 Reluctance to change existing diagnostic practices
      • 5.2.4.4 High cost of devices
      • 5.2.4.5 Product recalls
    • 5.2.5 EMERGING APPLICATIONS OF POINT-OF-CARE TESTING
      • 5.2.5.1 Sepsis biomarkers
      • 5.2.5.2 Stroke markers
      • 5.2.5.3 Thyroid testing
      • 5.2.5.4 DNA testing
      • 5.2.5.5 Endocrine testing

6 POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
  • 6.2 GLUCOSE MONITORING PRODUCTS
    • 6.2.1 GLUCOSE MONITORING PRODUCTS ACCOUNT FOR THE LARGEST SHARE OF THE POC DIAGNOSTICS MARKET
    • 6.2.2 POINT-OF-CARE GLUCOSE MONITORING PRODUCTS MARKET SPLIT, BY PLATFORM
    • 6.2.3 POINT-OF-CARE GLUCOSE MONITORING PRODUCTS MARKET SPLIT, BY MODE OF PURCHASE
    • 6.2.4 POINT-OF-CARE GLUCOSE MONITORING PRODUCTS MARKET SPLIT, BY END USER
    • 6.2.5 STRIPS
    • 6.2.6 METERS
    • 6.2.7 LANCETS & LANCING DEVICES
  • 6.3 CARDIOMETABOLIC MONITORING PRODUCTS
    • 6.3.1 POINT-OF-CARE CARDIOMETABOLIC MONITORING PRODUCTS MARKET SPLIT, BY PLATFORM
    • 6.3.2 POINT-OF-CARE CARDIOMETABOLIC MONITORING PRODUCTS MARKET SPLIT, BY MODE OF PURCHASE
    • 6.3.3 POINT-OF-CARE CARDIOMETABOLIC MONITORING PRODUCTS MARKET SPLIT, BY END USER
    • 6.3.4 CARDIAC MARKER TESTING PRODUCTS
      • 6.3.4.1 Rising government initiatives for CVD research will contribute to market growth
    • 6.3.5 POINT-OF-CARE CARDIAC MARKER TESTING PRODUCTS MARKET SPLIT, BY MODE OF PURCHASE
    • 6.3.6 POINT-OF-CARE CARDIAC MARKER TESTING PRODUCTS MARKET SPLIT, BY END USER
    • 6.3.7 BLOOD GAS/ELECTROLYTE TESTING PRODUCTS
      • 6.3.7.1 Technological advancements in blood gas/electrolyte products will drive the growth of this market segment
    • 6.3.8 POINT-OF-CARE BLOOD GAS/ELECTROLYTE TESTING PRODUCTS MARKET SPLIT, BY MODE OF PURCHASE
    • 6.3.9 POINT-OF-CARE BLOOD GAS/ELECTROLYTE TESTING PRODUCTS MARKET SPLIT, BY END USER
    • 6.3.10 HBA1C TESTING PRODUCTS
      • 6.3.10.1 Government initiatives are promoting the regular use of HbA1c testing
    • 6.3.11 POINT-OF-CARE HBA1C TESTING PRODUCTS MARKET SPLIT, BY MODE OF PURCHASE
    • 6.3.12 POINT-OF-CARE HBA1C TESTING PRODUCTS MARKET SPLIT, BY END USER
  • 6.4 INFECTIOUS DISEASE TESTING PRODUCTS
    • 6.4.1 POINT-OF-CARE INFECTIOUS DISEASE TESTING PRODUCTS MARKET SPLIT, BY PLATFORM
    • 6.4.2 POINT-OF-CARE INFECTIOUS DISEASE TESTING PRODUCTS MARKET SPLIT, BY MODE OF PURCHASE
    • 6.4.3 POINT-OF-CARE INFECTIOUS DISEASE TESTING PRODUCTS MARKET SPLIT, BY END USER
    • 6.4.4 INFLUENZA TESTING PRODUCTS
      • 6.4.4.1 Rising influenza prevalence has driven the demand for influenza testing products
    • 6.4.5 POINT-OF-CARE INFLUENZA TESTING PRODUCTS MARKET SPLIT, BY MODE OF PURCHASE
    • 6.4.6 POINT-OF-CARE INFLUENZA TESTING PRODUCTS MARKET SPLIT, BY END USER
    • 6.4.7 HIV TESTING PRODUCTS
      • 6.4.7.1 Rising prevalence of HIV to drive market growth
    • 6.4.8 POINT-OF-CARE HIV TESTING PRODUCTS MARKET SPLIT, BY MODE OF PURCHASE
    • 6.4.9 POINT-OF-CARE HIV TESTING PRODUCTS MARKET SPLIT, BY END USER
    • 6.4.10 HEPATITIS C TESTING PRODUCTS
      • 6.4.10.1 Central and East Asia are among the highly affected regions with Hepatitis C
    • 6.4.11 POINT-OF-CARE HEPATITIS C TESTING PRODUCTS MARKET SPLIT, BY MODE OF PURCHASE
    • 6.4.12 POINT-OF-CARE HEPATITIS C TESTING PRODUCTS MARKET SPLIT, BY END USER
    • 6.4.13 SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS
      • 6.4.13.1 Privacy and confidentiality issues are the key factors leading to the adoption of POC STD testing products
    • 6.4.14 POINT-OF-CARE STD TESTING PRODUCTS MARKET SPLIT, BY MODE OF PURCHASE
    • 6.4.15 POINT-OF-CARE STD TESTING PRODUCTS MARKET SPLIT, BY END USER
    • 6.4.16 HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS
      • 6.4.16.1 Rising prevalence of HAIs is the key factor driving market growth
    • 6.4.17 POINT-OF-CARE HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS MARKET SPLIT, BY MODE OF PURCHASE
    • 6.4.18 POINT-OF-CARE HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS MARKET SPLIT, BY END USER
    • 6.4.19 RESPIRATORY INFECTION TESTING PRODUCTS
      • 6.4.19.1 POCT products for the diagnosis of respiratory infections offer lower sensitivity as compared to other tests
    • 6.4.20 POINT-OF-CARE RESPIRATORY INFECTION TESTING PRODUCTS MARKET SPLIT, BY MODE OF PURCHASE
    • 6.4.21 POINT-OF-CARE RESPIRATORY INFECTION TESTING PRODUCTS MARKET SPLIT, BY END USER
    • 6.4.22 TROPICAL DISEASE TESTING PRODUCTS
      • 6.4.22.1 Increasing government funding for the use of POC in tropical disease testing will support market growth
    • 6.4.23 POINT-OF-CARE TROPICAL DISEASE TESTING PRODUCTS MARKET SPLIT, BY MODE OF PURCHASE
    • 6.4.24 POINT-OF-CARE TROPICAL DISEASE TESTING PRODUCTS MARKET SPLIT, BY END USER
    • 6.4.25 OTHER INFECTIOUS DISEASE TESTING PRODUCTS
    • 6.4.26 POINT-OF-CARE OTHER INFECTIOUS DISEASE TESTING PRODUCTS MARKET SPLIT, BY MODE OF PURCHASE
    • 6.4.27 POINT-OF-CARE OTHER INFECTIOUS DISEASE TESTING PRODUCTS MARKET SPLIT, BY END USER
  • 6.5 COAGULATION MONITORING PRODUCTS
    • 6.5.1 POINT-OF-CARE COAGULATION MONITORING PRODUCTS MARKET SPLIT, BY PLATFORM
    • 6.5.2 POINT-OF-CARE COAGULATION MONITORING PRODUCTS MARKET SPLIT, BY MODE OF PURCHASE
    • 6.5.3 POINT-OF-CARE COAGULATION MONITORING PRODUCTS MARKET SPLIT, BY END USER
    • 6.5.4 PT/INR TESTING PRODUCTS
      • 6.5.4.1 PT/INR is one of the most commonly used coagulation monitoring methods
    • 6.5.5 POINT-OF-CARE PT/INR TESTING PRODUCTS MARKET SPLIT, BY MODE OF PURCHASE
    • 6.5.6 POINT-OF-CARE PT/INR TESTING PRODUCTS MARKET SPLIT, BY END USER
    • 6.5.7 ACT/APTT TESTING PRODUCTS
      • 6.5.7.1 Rising number of patients undergoing angioplasty and dialysis globally to support market growth
    • 6.5.8 POINT-OF-CARE ACT/APTT TESTING PRODUCTS MARKET SPLIT, BY MODE OF PURCHASE
    • 6.5.9 POINT-OF-CARE ACT/APTT TESTING PRODUCTS MARKET SPLIT, BY END USER
  • 6.6 PREGNANCY & FERTILITY TESTING PRODUCTS
    • 6.6.1 POINT-OF-CARE PREGNANCY & FERTILITY TESTING PRODUCTS MARKET SPLIT, BY PLATFORM
    • 6.6.2 POINT-OF-CARE PREGNANCY & FERTILITY TESTING PRODUCTS MARKET SPLIT, BY MODE OF PURCHASE
    • 6.6.3 POINT-OF-CARE PREGNANCY & FERTILITY TESTING PRODUCTS MARKET SPLIT, BY END USER
    • 6.6.4 PREGNANCY TESTING PRODUCTS
      • 6.6.4.1 Rising inclination toward home testing to support market growth
    • 6.6.5 POINT-OF-CARE PREGNANCY TESTING PRODUCTS MARKET SPLIT, BY MODE OF PURCHASE
    • 6.6.6 POINT-OF-CARE PREGNANCY TESTING PRODUCTS MARKET SPLIT, BY END USER
    • 6.6.7 FERTILITY TESTING PRODUCTS
      • 6.6.7.1 Increasing awareness of fertility testing to drive market growth
    • 6.6.8 POINT-OF-CARE FERTILITY TESTING PRODUCTS MARKET SPLIT, BY MODE OF PURCHASE
    • 6.6.9 POINT-OF-CARE FERTILITY TESTING PRODUCTS MARKET SPLIT, BY END USER
  • 6.7 TUMOR/CANCER MARKER TESTING PRODUCTS
    • 6.7.1 INCREASING INVESTMENTS FOR RESEARCH RELATED TO POC CANCER TESTING ARE DRIVING MARKET GROWTH
    • 6.7.2 POINT-OF-CARE TUMOR/CANCER MARKER TESTING PRODUCTS MARKET SPLIT, BY PLATFORM
    • 6.7.3 POINT-OF-CARE TUMOR/CANCER MARKER TESTING PRODUCTS MARKET SPLIT, BY MODE OF PURCHASE
    • 6.7.4 POINT-OF-CARE TUMOR/CANCER MARKER TESTING PRODUCTS MARKET SPLIT, BY END USER
  • 6.8 URINALYSIS TESTING PRODUCTS
    • 6.8.1 RISING PREVALENCE OF URINARY TRACT INFECTIONS IS DRIVING MARKET GROWTH
    • 6.8.2 POINT-OF-CARE URINALYSIS TESTING PRODUCTS MARKET SPLIT, BY PLATFORM
    • 6.8.3 POINT-OF-CARE URINALYSIS TESTING PRODUCTS MARKET SPLIT, BY MODE OF PURCHASE
    • 6.8.4 POINT-OF-CARE URINALYSIS TESTING PRODUCTS MARKET SPLIT, BY END USER
  • 6.9 CHOLESTEROL TESTING PRODUCTS
    • 6.9.1 RISING OBESITY LEVELS & CARDIOVASCULAR DISORDER INCIDENCE ARE THE KEY FACTORS SUPPORTING MARKET GROWTH
    • 6.9.2 POINT-OF-CARE CHOLESTEROL TESTING PRODUCTS MARKET SPLIT, BY PLATFORM
    • 6.9.3 POINT-OF-CARE CHOLESTEROL TESTING PRODUCTS MARKET SPLIT, BY MODE OF PURCHASE
    • 6.9.4 POINT-OF-CARE CHOLESTEROL TESTING PRODUCTS MARKET SPLIT, BY END USER
  • 6.10 HEMATOLOGY TESTING PRODUCTS
    • 6.10.1 PREFERENCE FOR LABORATORY-BASED TESTS AMONG USERS WILL IMPEDE MARKET GROWTH
    • 6.10.2 POINT-OF-CARE HEMATOLOGY TESTING PRODUCTS MARKET SPLIT, BY PLATFORM
    • 6.10.3 POINT-OF-CARE HEMATOLOGY TESTING PRODUCTS MARKET SPLIT, BY MODE OF PURCHASE
    • 6.10.4 POINT-OF-CARE HEMATOLOGY TESTING PRODUCTS MARKET SPLIT, BY END USER
  • 6.11 DRUGS-OF-ABUSE TESTING PRODUCTS
    • 6.11.1 RISING CONSUMPTION OF ILLICIT DRUGS HAS BOOSTED DEMAND FOR TESTING
    • 6.11.2 POINT-OF-CARE DRUGS-OF-ABUSE TESTING PRODUCTS MARKET SPLIT, BY PLATFORM
    • 6.11.3 POINT-OF-CARE DRUGS-OF-ABUSE TESTING PRODUCTS MARKET SPLIT, BY MODE OF PURCHASE
    • 6.11.4 POINT-OF-CARE DRUGS-OF-ABUSE TESTING PRODUCTS MARKET SPLIT, BY END USER
  • 6.12 FECAL OCCULT TESTING PRODUCTS
    • 6.12.1 LACK OF PROPER TRAINING IN THE USE OF FECAL OCCULT TESTING TO HAMPER MARKET ADOPTION
    • 6.12.2 POINT-OF-CARE FECAL OCCULT TESTING PRODUCTS MARKET SPLIT, BY PLATFORM
    • 6.12.3 POINT-OF-CARE FECAL OCCULT TESTING PRODUCTS MARKET SPLIT, BY MODE OF PURCHASE
    • 6.12.4 POINT-OF-CARE FECAL OCCULT TESTING PRODUCTS MARKET SPLIT, BY END USER
  • 6.13 OTHER POC PRODUCTS
    • 6.13.1 OTHER POC PRODUCTS MARKET SPLIT, BY PLATFORM
    • 6.13.2 OTHER POC PRODUCTS MARKET SPLIT, BY MODE OF PURCHASE
    • 6.13.3 OTHER POC PRODUCTS MARKET SPLIT, BY END USER

7 POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM

  • 7.1 INTRODUCTION
  • 7.2 LATERAL FLOW ASSAYS
    • 7.2.1 TECHNOLOGICAL ADVANCEMENTS AND INCREASING ADOPTION OF LFA ARE SUPPORTING MARKET GROWTH
  • 7.3 DIPSTICKS
    • 7.3.1 DIPSTICKS HELP IN THE ROUTINE ANALYSIS OF SEVERAL MEDICAL CONDITIONS
  • 7.4 MICROFLUIDICS
    • 7.4.1 MICROFLUIDICS IS AN EMERGING PLATFORM IN POC DIAGNOSTICS
  • 7.5 MOLECULAR DIAGNOSTICS
    • 7.5.1 INCREASING INITIATIVES BY MARKET PLAYERS FOR DEVELOPING POC MOLECULAR DIAGNOSTIC PRODUCTS TO DRIVE MARKET GROWTH
  • 7.6 IMMUNOASSAYS
    • 7.6.1 RISING INCIDENCE OF CANCER AND GROWING AWARENESS ABOUT IMMUNOASSAY PLATFORMS TO SUPPORT MARKET GROWTH

8 POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE

  • 8.1 INTRODUCTION
  • 8.2 PRESCRIPTION-BASED PRODUCTS
    • 8.2.1 GROWING PREVALENCE OF LIFESTYLE DISEASES AND FAVORABLE REIMBURSEMENT HAVE DRIVEN MARKET GROWTH
  • 8.3 OTC PRODUCTS
    • 8.3.1 RISING FOCUS ON HOME CARE IS EXPECTED TO BOOST DEMAND FOR OTC TESTING IN THE COMING YEARS

9 POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER

  • 9.1 INTRODUCTION
  • 9.2 OUTPATIENT HEALTHCARE & AMBULATORY CARE SETTINGS
    • 9.2.1 RAPID RESULT GENERATION AND AVAILABILITY OF IMMEDIATE PATIENT CARE ARE THE MAJOR FACTORS DRIVING THE GROWTH OF THIS END-USER SEGMENT
  • 9.3 HOSPITALS/CRITICAL CARE CENTERS
    • 9.3.1 HOSPITALS ARE AMONG THE LARGEST END USERS OF POC DIAGNOSTICS
  • 9.4 HOME CARE SETTINGS
    • 9.4.1 INCREASING INCLINATION TOWARDS HOME HEALTHCARE IS DRIVING THE GROWTH OF THIS END-USER SEGMENT
  • 9.5 OTHER END USERS

10 POINT-OF-CARE DIAGNOSTICS MARKET, BY REGION

  • 10.1 INTRODUCTION
  • 10.2 NORTH AMERICA
    • 10.2.1 US
      • 10.2.1.1 US dominated the North American Market in 2019
    • 10.2.2 CANADA
      • 10.2.2.1 Rising government initiatives to support the growth of the POC diagnostics market in Canada
  • 10.3 EUROPE
    • 10.3.1 GERMANY
      • 10.3.1.1 Germany accounted for the largest share of the European market
    • 10.3.2 FRANCE
      • 10.3.2.1 Growing public-private collaborations for product development to drive market growth
    • 10.3.3 UK
      • 10.3.3.1 Growing awareness of the benefits offered by POC diagnostics to support market growth in the UK
    • 10.3.4 REST OF EUROPE
  • 10.4 ASIA PACIFIC
    • 10.4.1 JAPAN
      • 10.4.1.1 Japan to dominate the APAC POC diagnostics market during the forecast period
    • 10.4.2 CHINA
      • 10.4.2.1 Rising investments by market players and the Chinese government to drive the growth of the POC diagnostics market in China
    • 10.4.3 INDIA
      • 10.4.3.1 High burden of chronic diseases to support market growth
    • 10.4.4 REST OF ASIA PACIFIC
  • 10.5 LATIN AMERICA
    • 10.5.1 BRAZIL
      • 10.5.1.1 Rising prevalence of diabetes to support market growth in Brazil
    • 10.5.2 MEXICO
      • 10.5.2.1 Rising prevalence of diabetes and cancer to support market growth in Mexico
    • 10.5.3 REST OF LATIN AMERICA
    • 10.5.4 MIDDLE EAST & AFRICA
      • 10.5.4.1 Rising prevalence of cancer to support market growth in the MEA

11 COMPETITIVE LANDSCAPE

  • 11.1 INTRODUCTION
  • 11.2 GLOBAL MARKET SHARE ANALYSIS, 2018
  • 11.3 COMPETITIVE SCENARIO
    • 11.3.1 PRODUCT LAUNCHES, ENHANCEMENTS, AND APPROVALS
    • 11.3.2 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
    • 11.3.3 ACQUISITIONS
  • 11.4 VENDOR DIVE OVERVIEW
  • 11.5 VENDOR INCLUSION CRITERIA
  • 11.6 VENDOR DIVE
    • 11.6.1 VISIONARY LEADERS
    • 11.6.2 INNOVATORS
    • 11.6.3 DYNAMIC DIFFERENTIATORS
    • 11.6.4 EMERGING COMPANIES

12 COMPANY PROFILES

(Business overview, Products and Services offered, Recent developments, MNM view)*

  • 12.1 ABBOTT LABORATORIES
  • 12.2 BECTON, DICKINSON AND COMPANY
  • 12.3 CHEMBIO DIAGNOSTICS
  • 12.4 DANAHER CORPORATION
  • 12.5 JOHNSON & JOHNSON
  • 12.6 ROCHE DIAGNOSTICS (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD.)
  • 12.7 SIEMENS HEALTHINEERS GROUP
  • 12.8 EKF DIAGNOSTICS
  • 12.9 QUIDEL
  • 12.10 TRINITY BIOTECH
  • 12.11 ACCUBIOTECH
  • 12.12 INSTRUMENTATION LABORATORY (A WERFEN COMPANY)
  • 12.13 NOVA BIOMEDICAL
  • 12.14 PTS DIAGNOSTICS (A PART OF SINOCARE, INC.)
  • 12.15 SEKISUI DIAGNOSTICS

Business overview, Products and Services offered, Recent developments, MNM view might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 AVAILABLE CUSTOMIZATIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS

LIST OF TABLES

  • TABLE 1: RECENT WAIVERS FOR MARKET PRODUCTS
  • TABLE 2: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 3: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 4: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY PLATFORM, 2017-2024 (USD MILLION)
  • TABLE 5: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY MODE OF PURCHASE, 2017-2024 (USD MILLION)
  • TABLE 6: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 7: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 8: GLUCOSE MONITORING STRIPS MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 9: GLUCOSE MONITORING METERS MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 10: GLUCOSE MONITORING LANCETS & LANCING DEVICES MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 11: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 12: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY PLATFORM, 2017-2024 (USD MILLION)
  • TABLE 13: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY MODE OF PURCHASE, 2017-2024 (USD MILLION)
  • TABLE 14: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 15: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 16: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY MODE OF PURCHASE, 2017-2024 (USD MILLION)
  • TABLE 17: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 18: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 19: POINT-OF-CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY MODE OF PURCHASE, 2017-2024 (USD MILLION)
  • TABLE 20: POINT-OF-CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 21: POINT-OF-CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 22: POINT-OF-CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS, BY MODE OF PURCHASE, 2017-2024 (USD MILLION)
  • TABLE 23: POINT-OF-CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 24: POINT-OF-CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 25: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 26: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY PLATFORM, 2017-2024 (USD MILLION)
  • TABLE 27: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY MODE OF PURCHASE, 2017-2024 (USD MILLION)
  • TABLE 28: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 29: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 30: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY MODE OF PURCHASE, 2017-2024 (USD MILLION)
  • TABLE 31: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 32: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 33: POINT-OF-CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY MODE OF PURCHASE, 2017-2024 (USD MILLION)
  • TABLE 34: POINT-OF-CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 35: POINT-OF-CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 36: POINT-OF-CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY MODE OF PURCHASE, 2017-2024 (USD MILLION)
  • TABLE 37: POINT-OF-CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 38: POINT-OF-CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 39: POINT-OF-CARE DIAGNOSTICS MARKET FOR STD TESTING PRODUCTS, BY MODE OF PURCHASE, 2017-2024 (USD MILLION)
  • TABLE 40: POINT-OF-CARE DIAGNOSTICS MARKET FOR STD TESTING PRODUCTS, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 41: POINT-OF-CARE DIAGNOSTICS MARKET FOR STD TESTING PRODUCTS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 42: POINT-OF-CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY MODE OF PURCHASE, 2017-2024 (USD MILLION)
  • TABLE 43: POINT-OF-CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 44: POINT-OF-CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 45: POINT-OF-CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY MODE OF PURCHASE, 2017-2024 (USD MILLION)
  • TABLE 46: POINT-OF-CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 47: POINT-OF-CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 48: POINT-OF-CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY MODE OF PURCHASE, 2017-2024 (USD MILLION)
  • TABLE 49: POINT-OF-CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 50: POINT-OF-CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 51: POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY MODE OF PURCHASE, 2017-2024 (USD MILLION)
  • TABLE 52: POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 53: POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 54: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 55: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY PLATFORM, 2017-2024 (USD MILLION)
  • TABLE 56: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY MODE OF PURCHASE, 2017-2024 (USD MILLION)
  • TABLE 57: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 58: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 59: POINT-OF-CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS, BY MODE OF PURCHASE, 2017-2024 (USD MILLION)
  • TABLE 60: POINT-OF-CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 61: POINT-OF-CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 62: POINT-OF-CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY MODE OF PURCHASE, 2017-2024 (USD MILLION)
  • TABLE 63: POINT-OF-CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 64: POINT-OF-CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 65: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY PLATFORM, 2017-2024 (USD MILLION)
  • TABLE 66: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY MODE OF PURCHASE, 2017-2024 (USD MILLION)
  • TABLE 67: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 68: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 69: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 70: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY MODE OF PURCHASE, 2017-2024 (USD MILLION)
  • TABLE 71: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 72: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 73: POINT-OF-CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY MODE OF PURCHASE, 2017-2024 (USD MILLION)
  • TABLE 74: POINT-OF-CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 75: POINT-OF-CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 76: POINT-OF-CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY PLATFORM, 2017-2024 (USD MILLION)
  • TABLE 77: POINT-OF-CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY MODE OF PURCHASE, 2017-2024 (USD MILLION)
  • TABLE 78: POINT-OF-CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 79: POINT-OF-CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 80: POINT-OF-CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY PLATFORM, 2017-2024 (USD MILLION)
  • TABLE 81: POINT-OF-CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY MODE OF PURCHASE, 2017-2024 (USD MILLION)
  • TABLE 82: POINT-OF-CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 83: POINT-OF-CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 84: POINT-OF-CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY PLATFORM, 2017-2024 (USD MILLION)
  • TABLE 85: POINT-OF-CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY MODE OF PURCHASE, 2017-2024 (USD MILLION)
  • TABLE 86: POINT-OF-CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 87: POINT-OF-CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 88: POINT-OF-CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY PLATFORM, 2017-2024 (USD MILLION)
  • TABLE 89: POINT-OF-CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY MODE OF PURCHASE, 2017-2024 (USD MILLION)
  • TABLE 90: POINT-OF-CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 91: POINT-OF-CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 92: POINT-OF-CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY PLATFORM, 2017-2024 (USD MILLION)
  • TABLE 93: POINT-OF-CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY MODE OF PURCHASE, 2017-2024 (USD MILLION)
  • TABLE 94: POINT-OF-CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 95: POINT-OF-CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 96: POINT-OF-CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY PLATFORM, 2017-2024 (USD MILLION)
  • TABLE 97: POINT-OF-CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY MODE OF PURCHASE, 2017-2024 (USD MILLION)
  • TABLE 98: POINT-OF-CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 99: POINT-OF-CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 100: POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER POC PRODUCTS, BY PLATFORM, 2017-2024 (USD MILLION)
  • TABLE 101: POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER POC PRODUCTS, BY MODE OF PURCHASE, 2017-2024 (USD MILLION)
  • TABLE 102: POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER POC PRODUCTS, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 103: POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER POC PRODUCTS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 104: POC DIAGNOSTICS MARKET, BY PLATFORM, 2017-2024 (USD MILLION)
  • TABLE 105: LATERAL FLOW ASSAYS MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 106: DIPSTICKS MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 107: MICROFLUIDICS MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 108: MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 109: IMMUNOASSAYS MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 110: POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2017-2024 (USD MILLION)
  • TABLE 111: PRESCRIPTION-BASED PRODUCTS MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 112: OTC PRODUCTS MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 113: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 114: POINT-OF-CARE DIAGNOSTICS MARKET FOR OUTPATIENT HEALTHCARE & AMBULATORY CARE SETTINGS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 115: POINT-OF-CARE DIAGNOSTICS MARKET FOR HOSPITALS/CRITICAL CARE CENTERS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 116: POINT-OF-CARE DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 117: POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 118: POINT-OF-CARE DIAGNOSTICS MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 119: NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 120: NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 121: NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2017-2024 (USD MILLION)
  • TABLE 122: NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2017-2024 (USD MILLION)
  • TABLE 123: NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 124: US: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 125: CANADA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 126: EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 127: EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 128: EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2017-2024 (USD MILLION)
  • TABLE 129: EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2017-2024 (USD MILLION)
  • TABLE 130: EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 131: GERMANY: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 132: FRANCE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 133: UK: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 134: ROE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 135: APAC: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 136: APAC: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 137: APAC: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2017-2024 (USD MILLION)
  • TABLE 138: APAC: POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2017-2024 (USD MILLION)
  • TABLE 139: APAC: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 140: JAPAN: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 141: CHINA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 142: INDIA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 143: ROAPAC: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 144: LATAM: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 145: LATAM: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 146: LATAM: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2017-2024 (USD MILLION)
  • TABLE 147: LATAM: POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2017-2024 (USD MILLION)
  • TABLE 148: LATAM: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 149: BRAZIL: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 150: MEXICO: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 151: REST OF LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 152: MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 153: MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2017-2024 (USD MILLION)
  • TABLE 154: MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2017-2024 (USD MILLION)
  • TABLE 155: MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2017-2024 (USD MILLION)

LIST OF FIGURES

  • FIGURE 1: RESEARCH METHODOLOGY STEPS
  • FIGURE 2: RESEARCH DESIGN
  • FIGURE 3: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 4: RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
  • FIGURE 5: DATA TRIANGULATION
  • FIGURE 6: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2019 VS. 2024 (USD MILLION)
  • FIGURE 7: POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2019 VS. 2024 (USD MILLION)
  • FIGURE 8: POINT-OF-CARE DIAGNOSTICS MARKET SHARE, BY PLATFORM, 2019 VS. 2024
  • FIGURE 9: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2019 VS. 2024 (USD MILLION)
  • FIGURE 10: POINT-OF-CARE DIAGNOSTICS MARKET, BY REGION
  • FIGURE 11: GROWING GOVERNMENT SUPPORT IS DRIVING THE ADOPTION OF POC DEVICES ACROSS THE GLOBE
  • FIGURE 12: GLUCOSE MONITORING PRODUCTS SEGMENT TO DOMINATE THE POC DIAGNOSTICS MARKET DURING THE FORECAST PERIOD
  • FIGURE 13: ASIA PACIFIC MARKET TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 14: POC DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 15: POINT-OF-CARE DIAGNOSTICS MARKET: GROWTH FORECAST, BY REGION (2019-2024)
  • FIGURE 16: NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 17: APAC: POINT-OF-CARE DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 18: ROCHE DIAGNOSTICS HELD THE LEADING POSITION IN THE POINT-OF-CARE DIAGNOSTICS MARKET IN 2018
  • FIGURE 19: VENDOR DIVE: EVALUATION OVERVIEW
  • FIGURE 20: ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • FIGURE 21: BD: COMPANY SNAPSHOT
  • FIGURE 22: CHEMBIO DIAGNOSTICS: COMPANY SNAPSHOT
  • FIGURE 23: DANAHER CORPORATION: COMPANY SNAPSHOT
  • FIGURE 24: JOHNSON & JOHNSON: COMPANY SNAPSHOT
  • FIGURE 25: ROCHE DIAGNOSTICS: COMPANY SNAPSHOT
  • FIGURE 26: SIEMENS HEALTHINEERS GROUP: COMPANY SNAPSHOT
  • FIGURE 27: EKF DIAGNOSTICS: COMPANY SNAPSHOT
  • FIGURE 28: QUIDEL: COMPANY SNAPSHOT
  • FIGURE 29: TRINITY BIOTECH: COMPANY SNAPSHOT
Back to Top